Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Receivables - Net (2020 - 2023)

Historic Receivables - Net for Revolution Medicines (RVMD) over the last 4 years, with Q4 2023 value amounting to $1.3 million.

  • Revolution Medicines' Receivables - Net fell 7316.5% to $1.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.3 million, marking a year-over-year decrease of 7316.5%. This contributed to the annual value of $1.3 million for FY2023, which is 7316.5% down from last year.
  • As of Q4 2023, Revolution Medicines' Receivables - Net stood at $1.3 million, which was down 7316.5% from $309000.0 recorded in Q3 2023.
  • Revolution Medicines' 5-year Receivables - Net high stood at $7.6 million for Q1 2021, and its period low was $309000.0 during Q3 2023.
  • Over the past 4 years, Revolution Medicines' median Receivables - Net value was $5.4 million (recorded in 2022), while the average stood at $4.8 million.
  • Per our database at Business Quant, Revolution Medicines' Receivables - Net crashed by 725.79% in 2021 and then tumbled by 9374.49% in 2023.
  • Revolution Medicines' Receivables - Net (Quarter) stood at $6.4 million in 2020, then decreased by 7.26% to $5.9 million in 2021, then dropped by 21.18% to $4.7 million in 2022, then crashed by 73.16% to $1.3 million in 2023.
  • Its Receivables - Net stands at $1.3 million for Q4 2023, versus $309000.0 for Q3 2023 and $2.5 million for Q2 2023.